PDF(Pubmed)
Abstract：
UNASSIGNED: Obstructive sleep apnea (OSA) is a highly prevalent sleep-disordered breathing. It is associated with adverse co-morbidities, being the most scientific evidence of cardiovascular (CV) disease. Currently, OSA is measured through the apnea-hypopnea index (AHI), the total number of respiratory events per hour of sleep. However, different studies have questioned its utility in OSA management, highlighting the need to search for new parameters that better reflect the heterogeneity of the disease. Hypoxic burden (HB) has emerged as a novel biomarker that informs about the frequency, duration and depth of the desaturation related to the respiratory events. We conducted a systematic review in order to find publications about the heterogeneity of OSA measured by HB and its associations with future disease.
UNASSIGNED: Systematic review was conducted using PubMed and Web of Science. The terms \"sleep apne\" and \"hypoxic burden\" were used to look for publications from the date of inception to August 15, 2023. Inclusion criteria: articles in English published in peer-reviewed journals. Exclusion criteria: (1) not available publications; (2) duplicated articles; (3) letters, editorials, and congress communications; (4) articles not including information about HB as a specific biomarker of OSA.
UNASSIGNED: 33 studies were included. The results were classified in 2 main sections: (1) HB implication in the CV sphere: HB showed to be a better predictor of CV risk in OSA patients than traditional measures such as AHI with possible clinical management implication in OSA. (2) HB response to OSA treatment: pharmacological and nonpharmacological treatments have demonstrated to be effective in improving hypoxia measured through the HB.
UNASSIGNED: HB could be a better and more effective parameter than traditional measurements in terms of diagnosis, risk prediction and therapeutic decisions in patients with OSA. This measure could be incorporated in sleep units and could play a role in OSA management, driving the clinic to a more personalized medicine.
UNASSIGNED: Systematic review was conducted using PubMed and Web of Science. The terms \"sleep apne\" and \"hypoxic burden\" were used to look for publications from the date of inception to August 15, 2023. Inclusion criteria: articles in English published in peer-reviewed journals. Exclusion criteria: (1) not available publications; (2) duplicated articles; (3) letters, editorials, and congress communications; (4) articles not including information about HB as a specific biomarker of OSA.
UNASSIGNED: 33 studies were included. The results were classified in 2 main sections: (1) HB implication in the CV sphere: HB showed to be a better predictor of CV risk in OSA patients than traditional measures such as AHI with possible clinical management implication in OSA. (2) HB response to OSA treatment: pharmacological and nonpharmacological treatments have demonstrated to be effective in improving hypoxia measured through the HB.
UNASSIGNED: HB could be a better and more effective parameter than traditional measurements in terms of diagnosis, risk prediction and therapeutic decisions in patients with OSA. This measure could be incorporated in sleep units and could play a role in OSA management, driving the clinic to a more personalized medicine.
摘要：
■阻塞性睡眠呼吸暂停（OSA）是一种非常普遍的睡眠呼吸紊乱。它与不良合并症有关，是心血管（CV）疾病的最科学证据。目前,OSA是通过呼吸暂停低通气指数（AHI）来测量的，每小时睡眠呼吸事件的总数。然而,不同的研究质疑它在OSA管理中的效用，强调需要寻找更好地反映疾病异质性的新参数。低氧负荷（HB）已成为一种新颖的生物标志物，可告知频率，与呼吸事件相关的去饱和的持续时间和深度。我们进行了系统评价，以寻找有关HB测量的OSA异质性及其与未来疾病的关联的出版物。
■使用PubMed和WebofScience进行了系统评价。术语“睡眠apne”和“缺氧负担”用于寻找从开始之日起至2023年8月15日的出版物。纳入标准：在同行评审期刊上发表的英文文章。排除标准:(1)没有出版物；(2)重复文章；(3)信件，社论,和国会通讯；（4）文章不包括关于HB作为OSA特定生物标志物的信息。
■包括33项研究。结果分为2个主要部分：（1）CV领域中的HB含义：与传统措施（例如AHI）相比，HB对OSA患者的CV风险具有更好的预测作用，在OSA中可能具有临床管理意义。(2)HB对OSA治疗的反应:已证明药理学和非药理学治疗有效改善通过HB测量的缺氧。
■在诊断方面，HB可能是比传统测量更好，更有效的参数，OSA患者的风险预测和治疗决策。这项措施可以纳入睡眠单位，并可以在OSA管理中发挥作用，将诊所推向更个性化的医学。
■使用PubMed和WebofScience进行了系统评价。术语“睡眠apne”和“缺氧负担”用于寻找从开始之日起至2023年8月15日的出版物。纳入标准：在同行评审期刊上发表的英文文章。排除标准:(1)没有出版物；(2)重复文章；(3)信件，社论,和国会通讯；（4）文章不包括关于HB作为OSA特定生物标志物的信息。
■包括33项研究。结果分为2个主要部分：（1）CV领域中的HB含义：与传统措施（例如AHI）相比，HB对OSA患者的CV风险具有更好的预测作用，在OSA中可能具有临床管理意义。(2)HB对OSA治疗的反应:已证明药理学和非药理学治疗有效改善通过HB测量的缺氧。
■在诊断方面，HB可能是比传统测量更好，更有效的参数，OSA患者的风险预测和治疗决策。这项措施可以纳入睡眠单位，并可以在OSA管理中发挥作用，将诊所推向更个性化的医学。
